Shorted
Pyc Therapeutics logo
PYC

PYC Therapeutics

Pharmaceuticals, Biotechnology & Life Sciences

PYC Therapeutics is a clinical-stage biotech company focused on developing RNA therapies to address genetic diseases. Their proprietary RNA delivery platform aims to provide safer and more effective treatments by targeting the underlying causes of these diseases. The company is advancing a pipeline of novel therapies for eye, central nervous system, and kidney diseases.

Short position

short percentage0.82%
reported shorts8.1M
shares on issue983.510M

PYC Therapeutics (ASX:PYC) has 0.82% of its shares on issue reported as short positions as of 5 Oct 2026, or about 8,063,670 shares. Over the past 30 days that figure has risen 0.79 percentage points, and over 90 days it has risen 0.48 percentage points. Its highest recorded short interest was 1.09% in September 2026. PYC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

PYC Therapeutics (PYC) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
2d ago

PYC Therapeutics Issues 700,000 Shares After PYCAV Option Exercises at $1.70 on October 8, 2026

PYC Therapeutics Limited (ASX:PYC) has requested the listing of 700,000 fully paid ordinary shares on the ASX, issued on 8 October 2026 following the exercise of PYCAV options priced at AUD $1.70 each, with an expiry date of 26 October 2026. Key Points On 8 October 2026, 700,000 PYCAV options (expiring 26 October 2026, exercise price $1.70) were converted into an equal number of fully paid ordinary shares. The shares were issued at AUD $1.70 per security, with payment made in Australian dolla...

Continue reading
Kalkine
Neutral
2d ago

PYC Therapeutics Announces Termination of 100,000 PYCAZ Options Expiring May 2028 at $1.70 Exercise Price

PYC Therapeutics Limited (ASX:PYC) has informed the market about the termination of 100,000 unquoted PYCAZ options, which had an expiry date of 22 May 2028 and an exercise price of $1.70, effective from 8 October 2026. Key Highlights 100,000 PYCAZ options (expiry 22 May 2028, exercise price $1.70) terminated on 8 October 2026 Termination due to lapse of conditional rights as conditions were unmet or impossible to satisfy No payment was made by the company for the termination Post-termination,...

Continue reading
Kalkine
Neutral
3d ago

Which Milestone Comes Next for PYC Therapeutics (ASX:PYC)?

Highlights PYC Therapeutics has dosed the first patient in an extension study for kidney disease. The stock was among Monday's stronger healthcare gainers. Single-dose data in polycystic kidney disease is expected this calendar year. PYC Therapeutics (ASX:PYC) was among the stronger healthcare performers on Monday, extending a run that has made the RNA drug developer one of the sector's standout stocks over the past year, as the market looks ahead to its next data readout in polycystic kidney...

Continue reading
Kalkine
Neutral
15 Sept

PYC Therapeutics (ASX:PYC): The Biotech Story Getting Bigger

Highlights PYC Therapeutics is advancing a pipeline of RNA-based therapies targeting rare inherited diseases. PYC-003 is emerging as a key clinical programme focused on autosomal dominant polycystic kidney disease. Safety findings and upcoming efficacy data could become important milestones for the companys development story. Australias biotechnology sector is attracting renewed attention as local drug developers advance treatments for diseases with limited therapeutic options. Among the...

Continue reading
Kalkine
Positive
9 July

Can PYC Therapeutics (ASX:PYC) Strengthen Its Growth Strategy With a New CFO?

Highlights PYC Therapeutics has appointed an experienced biotechnology finance executive as its new Chief Financial Officer. The appointment brings international capital markets experience, including previous NASDAQ listing expertise. Clinical development and capital management remain central to the company's long-term strategy. PYC Therapeutics Ltd (ASX:PYC) has strengthened its executive leadership with the appointment of Thomas Ulmer as Chief Financial Officer, bri...

Continue reading